Hematology and Oncology Consultants PC

The trials here

What the 61 trials at this site are about, from their registry records.

Conditions

• Lung cancer15 trials
• Childhood cancers10 trials
• Ovarian cancer8 trials
• Colorectal cancer6 trials
• Melanoma6 trials
• Metastatic breast cancer5 trials
• Chronic lymphocytic leukaemia4 trials
• Bladder cancer3 trials
• Kidney cancer3 trials
• Liver and biliary tract cancer3 trials
• Pancreatic cancer3 trials
• Sarcoma3 trials
• and 19 more

Phase

• Phase 226 trials
• Phase 325 trials
• Phase 2/34 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Active, not recruiting40 trials
• Completed15 trials
• Suspended5 trials
• Terminated1 trial

Lead sponsor

• National Cancer Institute (NCI)36 trials
• SWOG Cancer Research Network11 trials
• ECOG-ACRIN Cancer Research Group8 trials
• Alliance for Clinical Trials in Oncology3 trials
• Children's Oncology Group2 trials
• and 1 more

Running trials

• Active, not recruiting

  Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

  NCT03516279· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

  NCT03793179· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

  NCT03698019· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

  NCT03701282· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

  NCT03737981· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

  NCT03595124· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

  NCT03609216· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

  NCT03654768· Phase 2· SWOG Cancer Research Network· Source

• Active, not recruiting

  Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

  NCT03660826· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

  NCT03228537· Phase 1· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

  NCT03516942· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

  NCT03419234· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02839707· Phase 2/3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

  NCT02642042· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

  NCT02595424· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

  NCT02311933· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

  NCT02257528· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

  NCT02306161· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

  NCT02196181· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT02048813· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT01896999· Phase 1/2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT01863550· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

  NCT01575548· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

  NCT01274338· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT00588770· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

  NCT00565851· Phase 3· National Cancer Institute (NCI)· Source

Closed trials

• Terminated

  Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

  NCT03737994· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

  NCT03694002· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

  NCT03602586· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916· Children's Oncology Group· Source

• Completed

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

  NCT03033576· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT02498600· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

  NCT02438722· Phase 2/3· SWOG Cancer Research Network· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209· Phase 3· National Cancer Institute (NCI)· Source